Ippei Hiramatsu
Papers
2
Total Citations
2
H-Index
1
About
Ippei Hiramatsu is a pioneering urologic surgeon whose research is redefining precision in robotic oncology. His work centers on two critical frontiers: optimizing predictive biomarkers for prostate cancer recurrence and advancing nephron-sparing techniques for renal cell carcinoma. In a landmark 2025 study, Hiramatsu demonstrated that the prostate-specific antigen decline rate in the first month post-surgery (PSADR1M) serves as a timely, powerful predictor of biochemical recurrence after robot-assisted radical prostatectomy—a finding that could revolutionize early intervention strategies. Simultaneously, he has pioneered the Minimum Layer Resection (MLR) method for robot-assisted partial nephrectomy, guided by virtual 3D imaging. This technique maximizes renal functional preservation by precisely excising only the tumor with minimal healthy tissue, achieving superior oncologic control while safeguarding kidney function. Though his most-cited papers currently hold 1 citation each, their recent publication signals emerging impact in a rapidly evolving field. Hiramatsu’s dual focus on predictive analytics and surgical innovation positions him as a rising authority in robotic urology, offering tangible tools to improve patient outcomes through earlier detection and more conservative, effective surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2